These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7909396)

  • 1. Neuropharmacology of anxiety: perspectives and prospects.
    Hamon M
    Trends Pharmacol Sci; 1994 Feb; 15(2):36-9. PubMed ID: 7909396
    [No Abstract]   [Full Text] [Related]  

  • 2. [The neurochemistry of anxiety (a review)].
    Orlikov AB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(11):116-20. PubMed ID: 1686952
    [No Abstract]   [Full Text] [Related]  

  • 3. Usefulness of animal models with newer anxiolytics.
    File SE
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():525A-526A. PubMed ID: 1354059
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists.
    Hughes J; Hunter JC; Woodruff GN
    Neuropeptides; 1991 Jul; 19 Suppl():85-9. PubMed ID: 1679213
    [No Abstract]   [Full Text] [Related]  

  • 5. [Design and synthesis of cholecystokinin-4 dipeptide analogues with anxiolytic and anxiogenic activities].
    Gudasheva TA; Kir'ianova EP; Kolik LG; Konstantinopol'skiĭ MA; Seredenin SB
    Bioorg Khim; 2007; 33(4):413-20. PubMed ID: 17886432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The serotoninergic mechanisms of anxiety and the action of tranquilizers (a review)].
    Komissarova RA; Komissarov IV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(5):140-4. PubMed ID: 1975713
    [No Abstract]   [Full Text] [Related]  

  • 7. Marine indole alkaloids: potential new drug leads for the control of depression and anxiety.
    Kochanowska-Karamyan AJ; Hamann MT
    Chem Rev; 2010 Aug; 110(8):4489-97. PubMed ID: 20380420
    [No Abstract]   [Full Text] [Related]  

  • 8. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies.
    Harro J
    Amino Acids; 2006 Oct; 31(3):215-30. PubMed ID: 16738800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
    Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
    Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacology of anxiolytics and their therapeutic use].
    Tada K
    Ryoikibetsu Shokogun Shirizu; 2003; (38):608-11. PubMed ID: 12877061
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice.
    Cao BJ; Rodgers RJ
    Psychopharmacology (Berl); 1998 Oct; 139(3):185-94. PubMed ID: 9784072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of serotonergic affect control.
    Kennett GA
    Adv Exp Med Biol; 1991; 294():231-43. PubMed ID: 1685293
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats.
    Kasahara K; Hashimoto S; Hattori T; Kawasaki K; Tsujita R; Nakazono O; Takao K; Kawakubo H; Nagatani T
    J Pharmacol Sci; 2015 Jan; 127(1):109-16. PubMed ID: 25704026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal models for anxiety and response to serotonergic drugs.
    Broekkamp CL; Berendsen HH; Jenck F; Van Delft AM
    Psychopathology; 1989; 22 Suppl 1():2-12. PubMed ID: 2567038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin antagonists induce anxiolytic and anxiogenic-like behavior in zebrafish in a receptor-subtype dependent manner.
    Nowicki M; Tran S; Muraleetharan A; Markovic S; Gerlai R
    Pharmacol Biochem Behav; 2014 Nov; 126():170-80. PubMed ID: 25284132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Easing the burden: treating refractory anxiety.
    Gorman JM
    CNS Spectr; 2004 Oct; 9(10):708. PubMed ID: 15448581
    [No Abstract]   [Full Text] [Related]  

  • 17. Limbic mechanisms of anxiolytics acting on 5-HT receptors.
    Płaźnik A; Kostowski W; Stefański R
    Pol J Pharmacol; 1994; 46(5):473-7. PubMed ID: 7894537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiolytic-like effects of DAIZAC, a selective high-affinity 5-HT(3) receptor antagonist, in the mouse elevated plus-maze.
    Zhang ZJ; Schmidt DE; de Paulis T; Trivedi BL; Onaivi ES; Ebert MH; Hewlett WA
    Pharmacol Biochem Behav; 2001; 69(3-4):571-8. PubMed ID: 11509218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New anxiolytics in development.
    Mosconi M; Chiamulera C; Recchia G
    Int J Clin Pharmacol Res; 1993; 13(6):331-44. PubMed ID: 7916335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anxiety at the frontier of molecular medicine.
    Weinberger DR
    N Engl J Med; 2001 Apr; 344(16):1247-9. PubMed ID: 11309643
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.